Immune Thrombocytopenia (ITP)NCT07046013
Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia
An observational study of Immune Thrombocytopenia (ITP), run by Sohag University.
Trial summary
Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- Immune Thrombocytopenia (ITP)
- What is being tested?
- Lactate dehydrogenase
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- Aug 2025to Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Sample collected from people newly diagnosed Immune thrombocytopenia at the time of diagnosis. Laboratory investigations: LDH_CBC_ESR_Bone marrow aspirate
Who may be able to join
- Thrombocytopenia patients at the time of diagnosis.
Who cannot join
- bone fractures _ bone diseases_ malignancy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Hassnaa Ahmed Abo elwafa, Prof.Dr contact
About this study
Official title: Relation Between Serum Lactate Dehydrogenase and Immune Thrombocytopenia
Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia
Read the detailed description
Immune thrombocytopenia is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation.
Lactate dehydrogenase is a group of oxidoreductase isoenzymes catalyzing the reversible reaction between pyruvate and lactate.
The LDH was found to be moderately high in patients with immune thrombocytopenia at the time of diagnosis.
- Conditions
- Immune Thrombocytopenia (ITP)
- Being tested
- Lactate dehydrogenase
- Medical subject headings
- Purpura, Thrombocytopenic, Idiopathic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lactate dehydrogenaseDiagnostic test
It's elevation at the time of diagnosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Relation between serum lactate dehydrogenase and immune thrombocytopenia
Measured: About 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study startAug 2025 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Immune Thrombocytopenia (ITP)Studies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shimaa Mahmoud Fahmy, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07046013
- Sponsor's protocol ID
- Soh-Med-25-5-7MS
- Status last verified
- Jun 2025
- First submitted
- 14 Jun 2025
- Last updated
- 1 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relation Between Serum Lactate Dehydrogenase and Immune Thrombocytopenia
- ClinicalTrials.gov ID
- NCT07046013
- Acronym / sponsor ID
- Soh-Med-25-5-7MS
- Conditions
- Immune Thrombocytopenia (ITP)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Aug 2025 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 1 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia
Detailed description
Immune thrombocytopenia is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation.
Lactate dehydrogenase is a group of oxidoreductase isoenzymes catalyzing the reversible reaction between pyruvate and lactate.
The LDH was found to be moderately high in patients with immune thrombocytopenia at the time of diagnosis.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Sample collected from people newly diagnosed Immune thrombocytopenia at the time of diagnosis. Laboratory investigations: LDH_CBC_ESR_Bone marrow aspirate
Key inclusion criteria (1 listed)
- Thrombocytopenia patients at the time of diagnosis.
Key exclusion criteria (1 listed)
- bone fractures _ bone diseases_ malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lactate dehydrogenaseIt's elevation at the time of diagnosis | Diagnostic test | – |
Primary outcome
Relation between serum lactate dehydrogenase and immune thrombocytopenia
Time frame: About 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Immune Thrombocytopenia (ITP)
RecruitingPhase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
RecruitingPhase 1/2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
RecruitingPhase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
RecruitingPhase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hassnaa Ahmed Abo elwafa, Prof.Dr contact
Questions about this trial
What is this clinical trial studying?
An observational study of Immune Thrombocytopenia (ITP), run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shaimaa Mahmoud Fahmy, Resident doctor (01149586292, shaimaa333mahmoud333@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relation between serum lactate dehydrogenase and immune thrombocytopenia (time frame: About 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2025.